Clinical Trial Update: Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study [Phase 2]

View source ↗

Summary

Clinical trial HALTAging-1 is a Phase 2 study targeting aging in survivors of blood cancers; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Leukemia
• Lymphoid Leukemia
• Monocytic Leukemia
• Multiple Myeloma
• Myeloid Leukemia
• Non-hodgkin Lymphoma

Snippet

Sponsor: University of Nebraska | Conditions: Hodgkin Lymphoma, Leukemia | Phase 2 | Status: NOT_YET_RECRUITING